AstraZeneca and Daiichi Sankyo enter collaboration to develop …
Jul 27, 2020 · AstraZeneca has entered into a new global development and commercialisation agreement with Daiichi Sankyo Company, Limited (Daiichi Sankyo) for DS-1062, Daiichi …
Daiichi Sankyo and AstraZeneca Enter New Global Development …
Jul 27, 2020 · AstraZeneca to pay Daiichi Sankyo up to $6 billion in total consideration, including a $1 billion upfront payment and up to an additional $5 billion contingent upon achievement of …
Daiichi Sankyo and AstraZeneca Announce Global Development …
Mar 29, 2019 · Daiichi Sankyo and AstraZeneca will jointly develop and commercialize [fam-] trastuzumab deruxtecan as a monotherapy or a combination therapy worldwide, except in …
ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved ... - AstraZeneca US
Apr 5, 2024 · Designed using Daiichi Sankyo’s proprietary DXd ADC technology, ENHERTU is the lead ADC in the oncology portfolio of Daiichi Sankyo and the most advanced program in …
ENHERTU® (fam-trastuzumab deruxtecan-nxki ... - AstraZeneca US
Oct 23, 2023 · Designed using Daiichi Sankyo’s proprietary DXd ADC technology, ENHERTU is the lead ADC in the oncology portfolio of Daiichi Sankyo and the most advanced program in …
Datroway (datopotamab deruxtecan) approved in the US for …
Jan 17, 2025 · AstraZeneca and Daiichi Sankyo entered into a global collaboration to jointly develop and commercialise Enhertu (trastuzumab deruxtecan) in March 2019 and Datroway in …
Enhertu approved in the US as first tumour-agnostic HER2 ... - AstraZeneca
Apr 6, 2024 · AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of adult patients with unresectable or metastatic HER2 …
Press Releases - Daiichi Sankyo US
3 days ago · Daiichi Sankyo (TSE: 4568) and AstraZeneca’s (LSE/STO/Nasdaq: AZN) ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been approved in the U.S. for the …
US FDA approves AstraZeneca & Daiichi Sankyo’s Enhertu to …
1 day ago · AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone …
AstraZeneca and Daiichi Sankyo win U.S. approval for breast …
Jan 18, 2025 · AstraZeneca and Daiichi Sankyo won U.S. approval for a novel breast cancer treatment, a milestone in the companies’ efforts to turn the medicine into a widely used …